← All indications
Pulmonary Embolism
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
Subtype terms (1)
More specific conditions that are subtypes of Pulmonary Embolism in the MeSH hierarchy.
- Pulmonary Infarction
1 drug approved
Drugs by status
Approved for this indication (14)
Phase 4 trials (23)
- sintrom
- acetylcysteine
- procaine benzylpenicillin
- clavulanate
- fluindione
- tenecteplase
- iopamidol
- monteplase
- motexafin gadolinium
- acetaminophen
- streptokinase
- acetylsalicylic acid
- coumarin
- furosemide
- tranexamic acid
- iodixanol
- sodium bicarbonate
- sodium chloride
- epoprostenol
- dalteparin
- nadroparin
- unfractionated heparin
- tinzaparin
Phase 3 trials (9)
Phase 2 trials (11)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (85)
- Eisai
- Aspen Pharmaceuticals
- Bracco
- Genentech
- Pfizer
- Bayer
- GlaxoSmithKline
- Medical Compression Systems
- Danish Heart Foundation
- National Heart, Lung, and Blood Institute (NHLBI)
- Huazhong University of Science and Technology
- Azienda Ospedaliera Universitaria Policlinico
- British Thoracic Society
- Cedars-Sinai Medical Center
- Cancer Research Network
- Harvard University
- Guangzhou Medical University
- Karadeniz Technical University
- Johns Hopkins University
- Monash University
- Northwell Health
- Qingdao University
- RWTH Aachen University
- Shanxi Medical University
- Silesian University of Medicine
- Spanish Society of Cardiology
- University of Kentucky
- University of Maryland
- University of Ottawa
- University of Palermo
- +55 more
Organization Involved with Phase 3 Indications (53)
- Ekos Corp
- AstraZeneca
- Sanofi
- Cyclomedica Australia PTY Limited
- Supergene, LLC
- Azienda U.S.L. 1 di Massa e Carrara
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
- Brown University
- Advent Health
- McMaster University
- Medical Center of Central Georgia
- Pirogov Russian National Research Medical University
- Red Cross Hospital Beverwijk
- Stanford University
- Universidad Complutense de Madrid
- University of Florida
- University of Groningen
- University of Lausanne
- University of Padua
- University of Rochester
- University of Zurich
- Columbia University
- University of Connecticut
- University of Copenhagen
- University of Basel
- Tsinghua University
- University of Western Brittany
- R. Adams Cowley Shock Trauma Center
- Christiana Hospital
- +23 more
Organization Involved with Phase 2 Indications (20)
- Eli Lilly
- Mallinckrodt
- Tasly Pharmaceuticals, Inc.
- Fundación Pública Andaluza
- National Institutes of Health (NIH)
- Aarhus University
- University of Pittsburgh
- Indiana University
- Mansoura University
- University of Seville
- Cardiff University
- Peking University
- University of Vienna
- Medpace, Inc.
- Medical University of Vienna
- University of Mississippi
- National Institute for Health Research, United Kingdom
- Trillium Health Partners
- The University of Texas, Dallas
- Angde Biotech Pharmaceutical Co., Ltd.
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (24)
- Marshfield Clinic Research Foundation
- ZonMw: The Netherlands Organisation for Health Research and Development
- Maastricht University
- Allegiance Health
- Hawler Medical University
- Newton-Wellesley Hospital
- Radboud University
- The New England Baptist Hospital
- Assiut University
- Fudan University
- Alliance Foundation Trials
- University of Toulouse
- Hebrew University
- Hawler Ministry of Health
- University of Sao Paulo
- LDS Hospital, Salt Lake City, Utah
- Department of Health and Human Services
- Netherlands Heart Foundation
- Israel Science Foundation
- Deseret Foundation
- United States - Israel Binational Science Foundation
- Government of Israel
- Chinese Academy of Medical Sciences
- Hospital Regional de Alta especialidad de Ixtapaluca